Details
Stereochemistry | RACEMIC |
Molecular Formula | C16H16ClN3O3S |
Molecular Weight | 365.835 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CC2=C(C=CC=C2)N1NC(=O)C3=CC=C(Cl)C(=C3)S(N)(=O)=O
InChI
InChIKey=NDDAHWYSQHTHNT-UHFFFAOYSA-N
InChI=1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)
DescriptionSources: http://www.drugbank.ca/drugs/DB00808Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/indapamide.html
Sources: http://www.drugbank.ca/drugs/DB00808
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/dosage/indapamide.html
Indapamide is an antihypertensive and a diuretic. It contains both a polar sulfamoyl chlorobenzamide moiety and a lipid- soluble methylindoline moiety. Indapamide blocks the slow component of delayed rectifier potassium current (IKs) without altering the rapid component (IKr) or the inward rectifier current. Specifically it blocks or antagonizes the action the proteins KCNQ1 and KCNE1. Indapamide is also thought to stimulate the synthesis of the vasodilatory hypotensive prostaglandin PGE2. Indapamide is used for the treatment of hypertension, alone or in combination with other antihypertensive drugs, as well as for the treatment of salt and fluid retention associated with congestive heart failure or edema from pregnancy (appropriate only in the management of edema of pathologic origin during pregnancy when clearly needed). Also used for the management of edema as a result of various causes.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1866 Sources: http://www.drugbank.ca/drugs/DB00808 |
|||
Target ID: CHEMBL4872 Sources: http://www.drugbank.ca/drugs/DB00808 |
|||
Target ID: CHEMBL3594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19119014 |
36.0 nM [Ki] | ||
Target ID: CHEMBL3242 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19119014 |
10.0 nM [Ki] | ||
Target ID: CHEMBL2326 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19119014 |
0.23 nM [Ki] | ||
Target ID: CHEMBL1876 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D00345 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Indapamide Approved UseIndapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs.
Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Launch Date9.0106561E11 |
|||
Primary | Indapamide Approved UseIndapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs.
Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Launch Date9.0106561E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
260 ng/mL |
5 g single, oral dose: 5 g route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
47.79 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23447043 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
919.52 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23447043 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14 h |
5 g single, oral dose: 5 g route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
23.23 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23447043 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25% |
5 g single, oral dose: 5 g route of administration: Oral experiment type: SINGLE co-administered: |
INDAPAMIDE blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: Page: p.261 |
unhealthy, 21 - 73 n = 311 Health Status: unhealthy Condition: Hypertension Age Group: 21 - 73 Sex: M+F Population Size: 311 Sources: Page: p.261 |
Disc. AE: Hypokalemia... AEs leading to discontinuation/dose reduction: Hypokalemia (0.64%) Sources: Page: p.261 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypokalemia | 0.64% Disc. AE |
2.5 mg 1 times / day multiple, oral Recommended Dose: 2.5 mg, 1 times / day Route: oral Route: multiple Dose: 2.5 mg, 1 times / day Sources: Page: p.261 |
unhealthy, 21 - 73 n = 311 Health Status: unhealthy Condition: Hypertension Age Group: 21 - 73 Sex: M+F Population Size: 311 Sources: Page: p.261 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
yes [IC50 11 uM] | ||||
yes [Inhibition 10 uM] | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
A comparative study of the activity of a new agent, indapamide, in essential arterial hypertension. | 1975 |
|
[Effects of perindopril and its combination with indapamide on risk stratification in patients with hypertension]. | 2001 |
|
Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. | 2001 |
|
Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. | 2001 |
|
Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. | 2001 Apr |
|
Indapamide plus perindopril--simpler treatment, better compliance. | 2001 Apr-May |
|
Comparison of spectrophotometric and an LC method for the determination perindopril and indapamide in pharmaceutical formulations. | 2001 Aug |
|
The lowering of blood pressure after stroke. | 2001 Dec 8 |
|
The lowering of blood pressure after stroke. | 2001 Dec 8 |
|
The lowering of blood pressure after stroke. | 2001 Dec 8 |
|
A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. | 2001 Feb |
|
Indapamide, a thiazide-like diuretic, decreases bone resorption in vitro. | 2001 Feb |
|
[New fixed combination for therapy of hypertension. "Softener" and "stimulant" supplement each other]. | 2001 Feb 1 |
|
Celecoxib-induced cholestatic hepatitis. | 2001 Feb 6 |
|
Coronary microvasculature alteration in hypertensive rats. Effect of treatment with a diuretic and an ACE inhibitor. | 2001 Jan |
|
Stripping voltammetric determination of indapamide in serum at castor oil-based carbon paste electrodes. | 2001 Jan |
|
Functional consequences of the arrhythmogenic G306R KvLQT1 K+ channel mutant probed by viral gene transfer in cardiomyocytes. | 2001 May 15 |
|
Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. | 2001 Nov |
|
[Clinical study of the month. Secondary prevention of cerebrovascular accident with perindopril: the PROGRESS study]. | 2001 Nov |
|
[Efficacy of a converting enzyme inhibitor in the prevention of recurrence of stroke]. | 2001 Nov 24 |
|
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs]. | 2001 Sep |
|
Very-low-dose combination of perindopril and indapamide as a novel strategy in first-line management of hypertension. | 2001 Sep |
|
Growth inhibitory activity of indapamide on vascular smooth muscle cells. | 2001 Sep 28 |
|
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. | 2001 Sep 29 |
|
[Changes of distensibility of the aorta in elderly patients during long-term therapy with various classes of hypotensive drugs (magnetic resonance tomography data)]. | 2002 |
|
[Tolerability and efficacy of retard form of indapamide in the treatment of hypertension in elderly patients (results of multicenter open non-comparative trial in Russian program ARGUS)]. | 2002 |
|
[Clinical assessment of efficacy and safety of noliprel in patients with hypertension]. | 2002 |
|
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. | 2002 |
|
Cutaneous drug reaction case reports: from the world literature. | 2002 |
|
[Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study]. | 2002 Aug |
|
Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study. | 2002 Dec |
|
Efficacious response with low-dose indapamide therapy in the treatment of type II diabetic patients with normal renal function or moderate renal insufficiency and moderate hypertension. | 2002 Jan-Feb |
|
Combined therapy with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke. | 2002 Mar-Apr |
|
[Reflexion of French experts on the key points of the symposium]. | 2002 Oct |
|
[The challenge to treat hypertensive patients with type 2 diabetes]. | 2002 Oct |
|
[Hypertension and microcirculation]. | 2002 Sep |
|
[Combination of low-dose perindopril/indapamide versus atenolol in the hypertensive patient. Effects on systolic pressure and arterial hemodynamics. REASON Study]. | 2002 Sep |
|
Indapamide induced syncope in a patient with long QT syndrome. | 2002 Sep |
|
Two derivative spectrophotometric determinations of indapamide in pharmaceutical dosage forms. | 2002 Sep 5 |
|
[Coversyl again]. | 2002 Sep 9 |
|
Progress and stroke--it's time to translate evidence into action. | 2002 Sep-Oct |
|
Drug-drug interactions among elderly patients hospitalized for drug toxicity. | 2003 Apr 2 |
|
Evaluation of the efficacy and tolerability of the combination delapril plus indapamide in the treatment of mild to moderate essential hypertension: a randomised, multicentre, controlled study. | 2003 Feb |
|
Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. | 2003 Feb |
|
Regression of left ventricular hypertrophy with echocardiography: some lessons from the LIVE study. | 2003 Jan |
|
Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: importance of triangulation, reverse use dependence, and instability. | 2003 Jan |
|
Mechanisms of adrenergic control of sino-atrial node discharge. | 2003 Mar-Apr |
|
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. | 2003 May |
|
Optimization of a solid-phase extraction method for determination of indapamide in biological fluids using high-performance liquid chromatography. | 2003 May 5 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/indapamide.html
Usual Adult Dose for Edema
Initial dose: 2.5 mg orally once a day.
Usual Adult Dose for Hypertension
Initial dose: 1.25 mg orally once a day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11204436
10(-4) M Indapamide decreased bone resorption in organ cultures and in cocultures of osteoblast-like cells and bone marrow cells in the presence of 10(-8) M 1,25-dihydroxyvitamin D3
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49185
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
NDF-RT |
N0000175420
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
WHO-VATC |
QC03BA11
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
WHO-ATC |
C03BA11
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
NDF-RT |
N0000175359
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
LIVERTOX |
503
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
WHO-ATC |
C09BX01
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
WHO-ATC |
C10BX13
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
||
|
WHO-VATC |
QC09BX01
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1433
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
248-012-7
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
INDAPAMIDE
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
M6245
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | Merck Index | ||
|
D007190
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
7203
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
3702
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
F089I0511L
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
DTXSID7044633
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
F089I0511L
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
Indapamide
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
CHEMBL406
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
1338801
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
757075
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
5893
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
SUB08169MIG
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
C29119
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
26807-65-8
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
3333
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | |||
|
5764
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY | RxNorm | ||
|
DB00808
Created by
admin on Fri Dec 16 21:34:58 UTC 2022 , Edited by admin on Fri Dec 16 21:34:58 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)